Brimonidine Tartrate CAS 70359-46-5 Assay 99.0%~101.0%
Shanghai Ruifu Chemical Co., Ltd. ndiyo inotungamira kugadzira Brimonidine Tartrate (CAS: 70359-46-5) ine mhando yepamusoro.Selective α2-adrenergic receptor agonist, mushonga unoshandiswa kurapa yakavhurika-angle glaucoma kana ocular hypertension.Ruifu Chemical inogona kupa kutumirwa kwepasirese, mutengo wemakwikwi, sevhisi yakanakisa, idiki uye yakawanda huwandu huripo.Tenga Brimonidine Tartrate,Please contact: alvin@ruifuchem.com
| Chemical Name | Brimonidine Tartrate |
| Mashoko anoreva zvakafanana | Brimonidine L-Tartrate;UK 14304 Tartrate;AGN190342 Tartrate;5-Bromo-N-(4,5-Dihydro-1H-Imidazol-2-yl)quinoxalin-6-Amine Tartrate;5-Bromo-N-(4,5-Dihydro-1H-Imidazol-2-yl)-6-Quinoxalinamine Tartrate;5-Bromo-N-(4,5-Dihydro-1H-Imidazol-2-yl)quinoxalin-6-Amine (2R,3R)-2,3-Dihydroxysuccinate |
| Stock Status | MuStock, Commercial Production |
| Nhamba yeCAS | 70359-46-5 |
| Molecular Formula | C11H10BrN5·C4H6O6 |
| Molecular Weight | 442.23 g/mol |
| Melting Point | 207.0~208.0℃(Zvita.) |
| Sensitive | Mhepo Inonzwa, Inonzwa Kupisa |
| COA & MSDS | Available |
| Origin | Shanghai, China |
| Sherufu Hupenyu | Mwedzi 24 Kana Yakachengetwa Zvakanaka |
| Category | API (Active Pharmaceutical Ingredient) |
| Brand | Ruifu Chemical |
| Items | Zvinotsanangurwa | Results |
| Chitarisiko | Muchena kana Yellowish zvishoma kana Zvishoma Brownish Powder | Conforms |
| Identification A | Specific Optical Rotation | Conforms |
| Kuzivikanwa B | Infrared Absorption Spectrophotometry | Conforms |
| Solubility | Inonyungudika mumvura, isinganyungudika muanhydrous ethanol uye mu toluene | Conforms |
| Specific Optical Rotation | +9.0° ~ +10.5° | +9.6° |
| Kurasika paKuomesa | ≤0.50% | 0.20% |
| Sulfated Ash | ≤0.20% | 0.07% |
| Heavy Metals | ≤20ppm | <20ppm |
| Related Substances | ||
| Kusachena Kwakatsanangurwa | ||
| N-(imidazolidin2ylidene)quinoxalin-6-amine | ≤0.10% | Conforms |
| 5-bromoqulinoxalin-6-amine | ≤0.10% | Conforms |
| Quinoxalin-6-amine | ≤0.10% | Conforms |
| 1-(5-bromoquinoxalin-6-yl)thiourea | ≤0.10% | Conforms |
| 2-(5-bromoquinoxalin-6-yl)guanidine | ≤0.10% | Conforms |
| 5-bromo-N-(1H-imidazol-2-yl)Quinoxalin-6-amine | ≤0.10% | Conforms |
| 1-(2-aminoethyl)-3-(5-bromoquinoxalin-6-yl) urea | ≤0.10% | Conforms |
| Zvisina Kutaurwa | ≤0.10% | Conforms |
| Total | ≤0.20% | 0.12% |
| Assay | 99.0% ~ 101.0% (paDried Basis) | 99.8% |
| Mhedziso | Ichi chigadzirwa nekuongorora zvinoenderana neBP2015 Standard | |
Package:Bhodhoro, Aluminium foil bag, 25kg/Cardboard Drum, kana zvinoenderana nezvinodiwa nemutengi.
Storage Condition:Chengetedza mudziyo wakavharwa zvakasimba uye chengeta munzvimbo inotonhorera, yakaoma (2~8℃) uye inofefeterwa nemhepo yakanaka kure nezvinhu zvisingaenderane.Dzivisa kutarisana nezuva rakananga, unyoro uye kupisa kwakanyanya.
KutumiraKuendesa kupasirese nemhepo, neFedEx / DHL Express.Ipa kutumirwa nekukurumidza uye kwakavimbika.
Kutenga sei?Please contactDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
Makore 15 Oupenyu?Tine makore anopfuura 15 ane ruzivo mukugadzira uye kutumira kunze kwemhando dzakasiyana-siyana dzepamusoro dzemishonga yepakati kana makemikari akanaka.
Main Markets?Tengesa kumusika wepamba, North America, Europe, India, Korea, Japan, Australia, nezvimwe.
Zvakanakira?Hunhu hwepamusoro, mutengo unokwanisika, masevhisi ehunyanzvi uye rutsigiro rwehunyanzvi, kuendesa nekukurumidza.
HunhuSimbiso?Strict quality control system.Midziyo yehunyanzvi yekuongorora inosanganisira NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, nezvimwe.
Samples?Zvigadzirwa zvakawanda zvinopa mahara emahara ekuongorora kwemhando, mutengo wekutumira unofanirwa kubhadharwa nevatengi.
Factory Audit?Factory audit inogamuchirwa.Ndapota itai nguva isati yasvika.
MOQ?Hapana MOQ.Kurongeka kudiki kunogamuchirwa.
Delivery Nguva? Kana mukati me stock, mazuva matatu kutumirwa anovimbiswa.
Transportation?Ne Express (FedEx, DHL), neMhepo, neGungwa.
Zvinyorwa?Mushure mekutengesa sevhisi: COA, MOA, ROS, MSDS, nezvimwe zvinogona kupihwa.
Custom Synthesis?Inogona kupa echinyakare synthesis masevhisi kuti aenderane nezvinodiwa zvako zvekutsvagisa.
Payment Terms?Proforma invoice inozotumirwa kutanga mushure mekusimbisa kurongeka, yakavharirwa ruzivo rwedu rwebhangi.Kubhadhara neT/T (Telex Transfer), PayPal, Western Union, nezvimwe.
Njodzi Yemashoko H301: Inokuvadza kana ikamedzwa.
Precautionary Statements
P501: Rasa zviri mukati / mudziyo kune inotenderwa marara chirimwa.
P270: Usadye, kunwa kana kuputa kana uchishandisa chigadzirwa ichi.
P264: Geza ganda zvakakwana mushure mekubata.
P301 + P310 + P330: KANA AKAMEDWA: Ibva wafonera POISON CENTER/chiremba.Shamba mukanwa.
P405: Chitoro chakakiyiwa.
Mitemo inoenderana
Zvekufambisa
Nhamba yeUN (DOT-AIR) UN2811
Kirasi (DOT-AIR) 6.1
Packing Group (TCI-A) III
Nhamba yeHS 2933.29.9000
Brimonidine Tartrate (CAS: 70359-46-5) inonyanya kusarudzwa α2-receptor blocker, yakabudirira yakagadzirwa neU.S. Company Allergan, iyo mishonga yemaziso.Inogona kuderedza intraocular pressure (IOP).Brimonidine Tartrate ophthalmic solution inotengeswa mumusika iBrimonidine Tartrate fomu, iri yakanaka IOP-inodzikisa mishonga yekusingaperi yakavhurika-angle glaucoma uye ocular hypertension kurapwa kwevarwere, asiwo kune argon laser IOP mazinga.Brimonidine Tartrate ophthalmic solution ine maitiro maviri echiito nekudzikisa aqueous kuseka kugadzirwa uye kuwedzera pigment layer ye liquid scleral outflow therapeutic zvinangwa.Mushure mekudonha muziso, mhedzisiro inokurumidza, uye inogona kusvika kumusoro kana uchishandisa kusvika 2h, uye nguva inoshanda inogona kuchengetedza 12h.Ropa rinongokwanisa kuona zvisaririra zvemishonga.Ichi chigadzirwa chine yekutanga-pass metabolism muchiropa, uye metabolites yakabudiswa muweti neitsvo.Systemic absorption uye kugovera haina kukanganiswa, uye vakweguru havadi kurongeka kwedosi.Brimonidine Tartrate ophthalmic solution kana ichienzaniswa nemamwe α-blockers, mafuta-soluble iduku, asi haisi nyore kudarika neropa-brain barrier uye haibudisi sedation, hypotension uye mamwe akafanana clonidine central adverse reactions.Brimonidine Tartrate Ophthalmic Solution inonyanya kusarudza kune α2-adrenergic receptors, uye α2/α1 chiyero chekugamuchira affinity inodarika ka1000.Mhedzisiro yealpha 2 receptors inogona kutungamira kuderera intraocular pressure.Uye basa reiyo alpha 1 receptors rinogona kutungamirira kune vascular contraction, eyelid retraction kana kuderedza uye kuwedzera kwemudzidzi.Kushandiswa kwenguva refu kwechigadzirwa ichi hakuzokonzeri kukurumidza desensitization.Mukuwedzera, kana ichienzaniswa ne-β-blockers, madonhwe emaziso eBrimonidine Tartrate nokuda kwemigumisiro miduku yemwoyo, haina simba pamapapu ekushanda, saka yakakodzera varwere vakaremara β-blockers.Uyezve, kana ikashandiswa yega β-blocker, haigone kuzadzisa zvinangwa zvekurapa, uye iwe unogona panguva imwe chete kuwedzera iyo FDA.
